Mercaptopurina Silver (Mercaptopurine Monohydrate)

Mercaptopurine acts as a purine analog that blocks the synthesis of new purine nucleotides. It is incorporated into DNA and RNA, leading to faulty nucleic acid formation, cell‑cycle arrest, and apoptosis of rapidly dividing cells, while also suppressing immune‑cell activation.

The dose of Mercaptopurina Silver is individualized by the prescribing clinician based on the patient’s diagnosis, age, weight, organ function, and concurrent therapies. Only a qualified health professional should determine the appropriate regimen.

Mercaptopurina Silver is classified as Pregnancy Category D, indicating evidence of fetal risk. It should be avoided in pregnancy unless the potential benefit justifies the risk. Breastfeeding is not recommended because the drug is excreted in milk and may harm the infant.

To request Mercaptopurina Silver, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Mercaptopurine belongs to the purine analog class, offering oral administration and a well‑characterised mechanism of inhibiting nucleic‑acid synthesis. Compared with agents such as azathioprine, it has a similar immunosuppressive profile but may require more intensive blood‑count monitoring due to a higher risk of myelosuppression.

Mercaptopurina Silver should be stored at temperatures below 25 °C, in its original packaging, protected from moisture and direct sunlight. Keeping the product in a dry, cool environment helps maintain its potency and stability.

Mercaptopurina Silver is supplied as an oral tablet and is taken by mouth with or without food, as directed by the prescribing clinician. Swallow the tablet whole; do not crush or chew unless specifically instructed.

The most serious risks include severe bone‑marrow suppression leading to neutropenia or anemia, hepatotoxicity, life‑threatening infections due to immunosuppression, and rare cases of pancreatitis. Regular laboratory monitoring is essential to detect these complications early.

Mercaptopurina Silver is contraindicated in patients with known hypersensitivity to mercaptopurine, those with severe hepatic or renal impairment where dose adjustment is not feasible, and pregnant women unless the benefit outweighs the risk. It should also be avoided in individuals receiving live vaccines.